LentiGlobin Administration to Sickle Cell Disease Patients: Effect on Serum Markers and Vaso-Occlusive Crisis.
| Autor: | Kumar H; Medicine and Surgery, Dow University of Health Sciences, Karachi, PAK., Sharma V; Medicine, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, IND., Wadhwa SS; Medicine, Government Medical College and Hospital, Nagpur, IND., Gowda DM; Psychiatry, Kempegowda Institute of Medical Sciences, Bengaluru, IND., Kaushik S; Internal Medicine, Bangalore Medical College, Bengaluru, IND., Joseph AM; Osteopathic Medicine, Nova Southeastern University Dr. Kiran C. Patel College of Osteopathic Medicine, Davie, USA., Karas M; Osteopathic Medicine, Nova Southeastern University Dr. Kiran C. Patel College of Osteopathic Medicine, Davie, USA., Quinonez J; Osteopathic Medicine/Neurology, Larkin Community Hospital Palm Springs Campus, Hialeah, USA.; Addiction Medicine, Brandon Regional Hospital, Brandon, USA., Furiato A; Emergency Medicine, Brandon Regional Hospital, Brandon, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Cureus [Cureus] 2024 Jan 08; Vol. 16 (1), pp. e51881. Date of Electronic Publication: 2024 Jan 08 (Print Publication: 2024). |
| DOI: | 10.7759/cureus.51881 |
| Abstrakt: | LentiGlobin, an innovative gene therapy, introduces a modified beta-globin gene that yields an anti-sickling hemoglobin variant. It boosts total hemoglobin levels, mitigates hemolysis, curtails inflammation, and addresses iron overload by reducing transfusion requirements. These changes, in turn, provide insights into disease mechanisms and treatment outcomes. Alterations in serum markers, such as hemoglobin levels and inflammatory biomarkers, can illuminate the therapeutic effectiveness of LentiGlobin and its impact on mitigating complications such as vaso-occlusive crises. Therefore, the purpose of this narrative review is to discuss the effects of LentiGlobin administration on diverse serum biomarkers and its correlation with vaso-occlusive crises in individuals with sickle cell disease (SCD). Competing Interests: HCA Healthcare Disclaimer: This research was supported (in whole or in part) by HCA Healthcare and/or an HCA Healthcare-affiliated entity. The views expressed in this publication represent those of the author(s) and do not necessarily represent the official views of HCA Healthcare or any of its affiliated entities (Copyright © 2024, Kumar et al.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|